CN113842452A - 治疗糖尿病的药物组合物及其制备方法 - Google Patents
治疗糖尿病的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN113842452A CN113842452A CN202110917964.2A CN202110917964A CN113842452A CN 113842452 A CN113842452 A CN 113842452A CN 202110917964 A CN202110917964 A CN 202110917964A CN 113842452 A CN113842452 A CN 113842452A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- pharmaceutical composition
- treating diabetes
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims description 14
- 239000003814 drug Substances 0.000 title abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 239000002994 raw material Substances 0.000 claims abstract description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 235000020235 chia seed Nutrition 0.000 claims description 24
- 239000000787 lecithin Substances 0.000 claims description 24
- 229940067606 lecithin Drugs 0.000 claims description 24
- 235000010445 lecithin Nutrition 0.000 claims description 24
- 229940088594 vitamin Drugs 0.000 claims description 23
- 229930003231 vitamin Natural products 0.000 claims description 23
- 235000013343 vitamin Nutrition 0.000 claims description 23
- 239000011782 vitamin Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 22
- 235000003599 food sweetener Nutrition 0.000 claims description 21
- 235000013406 prebiotics Nutrition 0.000 claims description 21
- 239000003765 sweetening agent Substances 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 20
- 241001264174 Cordyceps militaris Species 0.000 claims description 20
- 235000001465 calcium Nutrition 0.000 claims description 20
- 239000011575 calcium Substances 0.000 claims description 20
- 229910052791 calcium Inorganic materials 0.000 claims description 20
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 19
- 241000167854 Bourreria succulenta Species 0.000 claims description 19
- 240000003394 Malpighia glabra Species 0.000 claims description 19
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 19
- 235000019693 cherries Nutrition 0.000 claims description 19
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 18
- 241000934230 Anoectochilus roxburghii Species 0.000 claims description 17
- 241000237502 Ostreidae Species 0.000 claims description 17
- 244000134552 Plantago ovata Species 0.000 claims description 17
- 235000003421 Plantago ovata Nutrition 0.000 claims description 17
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 17
- 235000013325 dietary fiber Nutrition 0.000 claims description 17
- 235000020636 oyster Nutrition 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 229910052711 selenium Inorganic materials 0.000 claims description 17
- 239000011669 selenium Substances 0.000 claims description 17
- 235000011649 selenium Nutrition 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 241001076416 Dendrobium tosaense Species 0.000 claims description 15
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims description 15
- 235000010841 Silybum marianum Nutrition 0.000 claims description 15
- 235000013339 cereals Nutrition 0.000 claims description 15
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 14
- 244000182216 Mimusops elengi Species 0.000 claims description 14
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 244000272459 Silybum marianum Species 0.000 claims description 14
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 14
- 235000013557 nattō Nutrition 0.000 claims description 14
- 239000010903 husk Substances 0.000 claims description 13
- 235000013336 milk Nutrition 0.000 claims description 13
- 239000008267 milk Substances 0.000 claims description 13
- 210000004080 milk Anatomy 0.000 claims description 13
- 229940054810 white kidney bean extract Drugs 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 229930003451 Vitamin B1 Natural products 0.000 claims description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- 229960003495 thiamine Drugs 0.000 claims description 10
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims description 10
- 239000011716 vitamin B2 Substances 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 229940045997 vitamin a Drugs 0.000 claims description 10
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229930003779 Vitamin B12 Natural products 0.000 claims description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 9
- 239000011648 beta-carotene Substances 0.000 claims description 9
- 235000013734 beta-carotene Nutrition 0.000 claims description 9
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 9
- 229960002747 betacarotene Drugs 0.000 claims description 9
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 9
- 229960003080 taurine Drugs 0.000 claims description 9
- 235000019163 vitamin B12 Nutrition 0.000 claims description 9
- 239000011715 vitamin B12 Substances 0.000 claims description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims description 9
- 239000011726 vitamin B6 Substances 0.000 claims description 9
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 9
- 235000005282 vitamin D3 Nutrition 0.000 claims description 9
- 239000011647 vitamin D3 Substances 0.000 claims description 9
- 229940011671 vitamin b6 Drugs 0.000 claims description 9
- 229940021056 vitamin d3 Drugs 0.000 claims description 9
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 102000004407 Lactalbumin Human genes 0.000 claims description 7
- 108090000942 Lactalbumin Proteins 0.000 claims description 7
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000021119 whey protein Nutrition 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229940034055 calcium aspartate Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 3
- 238000010298 pulverizing process Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 69
- 239000008280 blood Substances 0.000 abstract description 69
- 230000000694 effects Effects 0.000 abstract description 38
- 230000001603 reducing effect Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 abstract description 6
- 230000000378 dietary effect Effects 0.000 abstract description 4
- 206010013654 Drug abuse Diseases 0.000 abstract description 3
- 208000011117 substance-related disease Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 230000036039 immunity Effects 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000008855 peristalsis Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 vitamin a Chemical compound 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000719836 Anoectochilus formosanus Species 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 208000007784 diverticulitis Diseases 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 239000010813 municipal solid waste Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001646834 Mesona Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000006698 Spigelia anthelmia Species 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001601726 Stromatium Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000021278 navy bean Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种治疗糖尿病的药物组合物及其制备方法,涉及药物技术领域,本发明提供的治疗糖尿病的药物组合物,包括谷物膳食纤维、乳清蛋白、乳粉、针叶樱桃、枸杞、水飞蓟、白芸豆提取物、奇亚籽、圆苞车前子壳、蛹虫草、冬虫夏草、牡蛎肽、金线莲、卵磷脂、铁皮石斛、富硒酵母粉、纳豆粉、维生素、甜味剂、益生元和钙剂,通过特定组分的相互配合,使得该药物组合物能够有效控制血糖,恢复免疫力。并且,上述各组分均为药食同源原料,患者通过食补即可实现净化血液、降糖功效,绿色安全,无毒副作用,有效避免了药物滥用造成的伤害。
Description
技术领域
本发明涉及药物技术领域,尤其是涉及一种治疗糖尿病的药物组合物及其制备方法。
背景技术
随着人们生活水平不断提高,高血压患者已超2亿,且每年以一千万人数增加,糖尿病人已有9240万,且还有1.4亿人血糖还在升高,同时,心脑血管患者的人数也超过了2亿,占死亡人数的百分之三十一(每年960 万)。
三高人群困扰着我们几亿人的生活,而且三高需要终生吃药和打胰岛素,要从根本上解决三高问题,必须找到得三高的根源,找到根源从根源抓起,才能彻底解决问题。
通过研究发现,这些慢性病的根本原因是血液出现问题,其主要原因是饮食食品不安全,农作物使用农药化肥超标,养殖方面大量的激素和抗生素滥用,还有一些转基因食品,给人们胃肠道带来破坏,从而使我们的五脏六腑不堪重负,工作繁忙、胡吃海喝、饮食无规律。人体70%的免疫力来自肠道,80%的毒素靠肠道排出,99%的营养靠肠道吸收。肠道是人体最大免疫系统、排泄系统和吸收系统三大系统,如果这三个系统出现了问题,就会导致血液慢性病四高(高血压、高血糖、高血脂、高尿酸)。毒素排不出去,就会被人体吸收,进入血管,各种指标超标,带来终生吃药打针甚至并发症,所以说只要解决血液问题,这些都迎刃而解。
有鉴于此,特提出本发明。
发明内容
本发明的主要目的在于提供一种治疗糖尿病的药物组合物,以至少缓解现有技术中存在的技术问题之一。
本发明的第二个目的在于提供上述治疗糖尿病的药物组合物的制备方法。
本发明提供了一种治疗糖尿病的药物组合物,包括如下组分:
谷物膳食纤维、乳清蛋白、乳粉、针叶樱桃、枸杞、水飞蓟、白芸豆提取物、奇亚籽、圆苞车前子壳、蛹虫草、冬虫夏草、牡蛎肽、金线莲、卵磷脂、铁皮石斛、富硒酵母粉、纳豆粉、维生素、甜味剂、益生元和钙剂。
进一步地,按重量分数计包括:
谷物膳食纤维5~15份、乳清蛋白5~15份、乳粉5~15份、针叶樱桃5~15 份、枸杞5~15份、水飞蓟5~15份、白芸豆提取物5~15份、奇亚籽2~8份、圆苞车前子壳5~15份、蛹虫草5~15份、冬虫夏草2~8份、牡蛎肽5~15份、金线莲10~30份、卵磷脂5~15份、铁皮石斛2~8份、富硒酵母5~15份、纳豆5~15份、维生素5~15份、甜味剂2~8份、益生元5~15份和钙剂5~15 份。
进一步地,按重量分数计包括:
谷物膳食纤维10份、乳清蛋白10份、乳粉10份、针叶樱桃10份、枸杞10份、水飞蓟10份、白芸豆提取物10份、奇亚籽5份、圆苞车前子壳10份、蛹虫草10份、冬虫夏草5份、牡蛎肽10份、金线莲20份、卵磷脂10份、铁皮石斛5份、富硒酵母10份、纳豆10份、维生素10份、甜味剂5份、益生元10份和钙剂10份。
进一步地,所述维生素包括维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素D3、维生素B12、叶酸和β- 胡萝卜素中的一种或多种。
进一步地,所述维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素D3、维生素B12、叶酸和β-胡萝卜素的质量比为179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500。
进一步地,所述甜味剂包括木糖醇。
进一步地,所述益生元包括低聚果糖、低聚半乳糖、低聚木糖、低聚异麦芽糖、大豆低聚糖或菊粉中的一种或多种。
进一步地,所述钙剂包括天门冬氨酸钙。
另外,本发明还提供了上述的治疗糖尿病的药物组合物的制备方法,所述制备方法包括取配方中的各原料,磨粉后,得到所述治疗糖尿病的药物组合物。
进一步地,磨粉后还包括过筛的步骤,优选过150~250目筛,更有选过200目筛。
与现有技术相比,本发明具有如下有益效果:
本发明提供的治疗糖尿病的药物组合物,包括谷物膳食纤维、乳清蛋白、乳粉、针叶樱桃、枸杞、水飞蓟、白芸豆提取物、奇亚籽、圆苞车前子壳、蛹虫草、冬虫夏草、牡蛎肽、金线莲、卵磷脂、铁皮石斛、富硒酵母粉、纳豆粉、维生素、甜味剂、益生元和钙剂,通过特定组分的相互配合,使得该药物组合物能够有效控制血糖,恢复免疫力。并且,上述各组分均为药食同源原料,患者通过食补即可实现净化血液、降糖功效,绿色安全,无毒副作用,有效避免了药物滥用造成的伤害。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明的发明人通过研究发现,糖尿病、高血压、高血脂等慢性疾病的主要病因是血液病,其会导致糖尿病的并发症,以及心肌梗塞、中风、高尿酸痛风等。基于此,本发明提供了一种治疗糖尿病的药物组合物,包括如下组分:
谷物膳食纤维、乳清蛋白、乳粉、针叶樱桃、枸杞、水飞蓟、白芸豆提取物、奇亚籽、圆苞车前子壳、蛹虫草、冬虫夏草、牡蛎肽、金线莲、卵磷脂、铁皮石斛、富硒酵母粉、纳豆粉、维生素、甜味剂、益生元和钙剂。
病从口入,从食品解决问题(食疗),排出体内的毒素,调整血液浓度,达到酸碱中和,清除血栓,净化血液,对糖尿病高血压高血脂等疾病有较好疗效。本发明提供的治疗糖尿病的药物组合物,通过特定组分的相互配合,使得该药物组合物能够有效控制血糖,恢复免疫力。并且,上述各组分均为药食同源原料,患者通过食补即可实现降糖功效,绿色安全,无毒副作用,有效避免了药物滥用造成的伤害。
其中,冬虫夏草有补肺益肾、止血化痰、抗肿瘤、调解免疫力的作用。一般用于慢性咳嗽、气喘、肺结核、咳血。冬虫夏草可以提高心脏耐缺氧能力,降低心脏消耗,抗心律失常,可以减轻有毒物质对肝脏的损伤,避免肝纤维的发生。此外,通过调节免疫功能,增加抗病毒的能力,对病毒肝炎发挥有利作用。将冬虫夏草用于此配方,有健脾开胃、滋养肝肾、祛瘀散结及滋补健体的作用。将其混于治疗糖尿病的药物组合物,滋而不腻,补而不柔,最适宜膳食饮用。也适用于各种骨肿瘤和慢性病人。
牡蛎肽,是属于一种高蛋白低热量的食物,而且含有比较丰富的矿物质,比如钙-锌-镁-磷-硒。牡蛎肽能够补肾,提高性功能,恢复疲劳,改善睡眠,增强皮肤的弹性。其具有明显抑制血小板聚集的作用,能够降低高血脂病人的血脂和中风TXA2含量,有利于胰岛素的分泌和利用。牡蛎肽又能使恶性肿瘤细胞对放射线敏感性增强,并对其生长有抑制作用。同时,牡蛎肽能提高男性的性功能,而且还能保护肝脏,增强免疫力,同时有降血糖,预防心脑血管疾病的作用。
富硒酵母,硒是在人体和动物体内起到一个平衡氧化还原作用,可以提高免疫力的同时硒是人体必备的微量元素。人类有很多疾病都是由生活环境污染造成的,硒则具有“天然解毒剂”的美称,包括1、氧化抗衰老; 2、保护和修复细胞;3、提高细胞携氧能力;4、增强人体免疫力;5、解毒排毒;6、恶性肿瘤的预防。
益生元:1、改善便秘和腹泻。益生元有促进有益菌大量繁殖的作用,便秘者肠内环境是碱性的,但有益菌在代谢过程中产生醋酸、乳酸等有机酸,可以促进肠道转为弱酸性,身体渗入的水分增多,刺激肠蠕动,从而缓解便秘。2、增强免疫力。双歧杆菌、乳酸杆菌等有益菌群利用益生元的营养会促进自身的生长和增殖,从而刺激巨噬细胞产生活性,被激活的巨噬细胞将分泌抗菌素,又会促进淋巴细胞分裂增殖,使肠道免疫器官生长,从而提高机体免疫力。3、促进矿物质元素的吸收。低聚糖类益生元经微生物发酵后可降低肠道pH值,提高矿物质溶解性,从而促进大肠中钙、镁等矿物质的吸收。4、调解脂质代谢。益生元在体内被有益菌发酵生成短链脂肪酸,如醋酸、丙酸、丁酸、乳酸等,这些有机酸类物质能使肠道内pH值和氨的浓度降低,有效抑制肠道腐败产物的生成,并促进肠道蠕动而促进排便,还可以改善脂质代谢。5、平衡肠内微生态。益生元可以帮助肠在经过抗生素,腹泻,压力或其它药物(非抗生素类)的干扰后恢复肠内细菌平衡,通过对某特定菌群的选择性的刺激而使平衡恢复。
金线莲:1、保护肝脏。金线莲能够直接作用于肝细胞膜,保护肝细胞的完整性,防止有害物质破坏肝细胞,同时也能防止肝脏新陈代谢,使受伤的细胞复活再生。增强细胞的氧化作用,使肝功能的各项检验值恢复到正常范围。2、降血压,金线莲有很好的降血压作用,而且能纠正脂质代谢异常,防止胆固醇过高,能促进体内前列腺的合成,防止血小板凝集,有明显抗血栓、抗动脉粥样斑块形成作用。3、止咳平喘,金线莲具有止咳平喘的功效,对气管痉挛有缓解作用,还可能改善肺功能,此外,金线莲对气管内分泌物有分解作用,可以减少痰液分泌,保护呼吸道畅通,临床上常用于治疗支气管炎、肺结核等症。4、改善体质,金线莲能增加身体的抵抗力,改善体质,提高淋巴细胞的转换率,并可延长抗体存在的时间,增加吞噬细胞的功能。5、辅助治疗癌症,金线莲能防止菌体细胞的繁殖,同时具有抗癌的功效,特别是对肺部的细胞组织具有强化抗菌的功效。6、金线莲不仅可以降低血浓度,还可以提高血液中胰岛素的含量。7、金线莲与高血压、中风、心脏病相关,根据研究指出,金线莲有非常良好的降血压作用,此外,还可以纠正脂质代谢的异常,防止胆固醇过高。经国内中医师证明在高血压胆固醇过高,动脉硬化、脑中风的异常和治疗上都要惊人的效果。
铁皮石斛,益胃生津,滋阴清热。1、最主要用于肾阳亏虚导致的视力下降,筋骨痿软,虚热等这些肾阳虚的病症,能通过滋养肾阳到达明显的去火效果,主要用于老年人的心血管疾病,比如冠心病、动脉硬化。2、一定的抗肿瘤作用。3、有对于肝胆疾病有一定作用。4、滋阴养目的作用。5、增强机体免疫力,增强抗病毒的能力。6、降血糖作用,铁皮枫斗对可能降低链脲毒素诱发的糖尿血糖值。铁皮石斛素有“千金草、救命仙草”之称。
卵磷脂:1、卵磷脂是血管的“清道夫”,具有乳化分解油脂的作用,能将附着血管壁上的胆固醇、中性细胞乳化成微颗粒,溶于血液,并运往肝脏被代谢排掉。可以降低血液表面的张力,使血液中的粘度降低,减少循环阻力,进而保证营养丰富,涵养充足的血液畅通无阻的流向大脑。2、卵磷脂中的胆碱对代谢有重要作用。如果体内胆碱不足,会造成脂肪在肝内大量积聚,形成脂肪肝,甚至发炎、肿胀、阻碍血液流通,造成肝细胞坏死。胆固醇过剩是肝硬化的主要原因,补充卵磷脂有助于肝细胞再生,可以促进脂肪降解排出,减少肝细胞内脂肪的沉积,从而可以有效的防止脂肪肝和肝硬化。3、使用卵磷脂可以缓解糖尿病的某些症状,对同时伴有动脉硬化的糖尿病患者缓解效果尤为显著。4、卵磷脂还可以消除疲劳,激化脑细胞改善因精神紧张引起的急躁、易怒、失眠等症状。5、卵磷脂还是美容养颜的保健品。如果卵磷脂缺乏,就会降低皮肤细胞的再生能力,导致皮肤粗糙,出现皱纹。适当摄取卵磷脂,皮肤再生活力可以得到保障,皮肤相对有光泽。卵磷脂所含的肌醇还是毛发的主要营养物质,能抑制脱发减少白发。
奇亚籽:1、通便利尿:奇亚籽进入到胃肠道中,可以吸收大量水分,促进胃肠道的蠕动,帮助机体及时排出堆积在体内的废物和毒素,促进机体健康,还能够预防消化道癌症。奇亚籽还能延缓碳水的分解,消化过程中能够给机体提供大量的能量。2、美容养颜:奇亚籽包含各种类型的维生素。其中维生素C和维生素E都是很好的美容养颜的成分,不仅能够抗氧化、清除自由基,避免自由基对细胞的损伤,还能够美白皮肤,延缓衰老,保持水分,减少胶原蛋白的流失。除了维生素以外,奇亚籽中还富含绿原酸,胡萝卜素和硒元素等多种抗氧化剂。3、调节血糖:奇亚籽能够调节机体内的胰岛素含量。胰岛素是控制机体内血糖代谢的重要激素,关系到血糖的水平。奇亚籽本身纤维素的形成也不会增加机体内的血糖含量,避免机体的血糖水平上升。4、保护心脑血管:奇亚籽中含有不饱和脂肪酸,不饱和脂肪酸是人体不可或缺的脂肪酸,能够促进胆固醇的脂化,降低血清中的胆固醇的浓度,降低血液粘稠度,改善血液微循环,亚麻酸能够软化血管,奇亚籽具有降血脂、降血压,保护心脑血管的功效,能够提高机体的免疫能力。5、保护心脏:奇亚籽中存在一种人体无法自主合成的重要脂肪酸,这种脂肪酸对于减少机体内的胆固醇含量,预防血栓和动脉硬化具有重要意义,可以预防多种心脑血管疾病。6、减肥瘦身:奇亚籽的纤维素的含量丰实,纤维素不仅饱腹感强,而且能够促进胃肠道的蠕动,促进机体吸收营养成分,排出代谢废物和毒素,奇亚籽可以促进人体排毒养颜,减肥瘦身。
纳豆:富含异黄酮和不饱和脂肪酸,能够促进人体的新陈代谢,加速人体肠胃蠕动,从而达到缓解便秘的症状,适量食用能够调节人体血糖以及在一定程度上溶解血栓,有助于预防心血管疾病。
圆苞车前子壳粉:1、润肠通便。2、心血管疾病、心脏病、降血脂。可溶性圆苞车前子纤维具有降低胆固醇的功效,在结肠内益生菌的作用下,圆苞车前子纤维中的糖类物质发酵分解为短链脂肪酸,从而阻止胆固醇的合成。3、肠道功能,预防结肠癌及其他肠胃疾病的患病机率4、糖尿病,血糖控制。圆苞车前子纤维有助于控制饭后的血糖上升。同时通过对血尿病的干预,圆苞车前草有助于减少糖尿病患者对胰岛素的需求量。5、憩室炎,在结肠内的物质体积增大,还能增加肠道蠕动,减少对肠壁的压力,这种调节作用有助于降低憩室炎的症状,防止憩室炎的发生。6、控制体重。
枸杞性甘、平,归肝肾经,具有滋补肝肾,养肝明目的功效,常与熟地、菊花、山药、山萸肉等药同用。现代医学研究表明,它含有胡萝卜素、甜菜碱、维生素A、维生素B1、维生素B2、维生素C和钙、磷、铁等,具有增强白细胞活性,促进肝细胞新生的药理作用,近代药理实验表明:枸杞子具有增强机体免疫功能,抑制肿瘤、降血糖、降血脂、抗疲劳等功能作用。《本草记言》认为,枸杞能使“气可充、血可补、阳可生、阴可长、风湿可去,又十全之妙焉”,。李时珍在《本草纲目》中把枸杞的主要功效归纳为“滋肾、润肺、明目”,简明扼要,符合实际。肾阴亏虚,肝血不足,引起腰膝酸软,头昏、耳鸣、遗精等症,宜用枸杞。
针叶樱桃:有预防感冒的作用,增强人体抵抗能力,还具有防癌抗癌的功效。针叶樱桃可以有效的促进胶原蛋白的合成,有促进伤口愈合的作用,还有去疤痕的功效。针叶樱桃能使细胞变得丰满,能减少皱纹,增强皮肤弹性,具有美容功效,并能有效保护大脑。针叶樱桃是强有力的抗氧化剂,防止自由基的对人体伤害。针叶樱桃还能有效的促进肠道对铁的吸收,提高肝脏对铁的利用率,有治疗缺铁性贫血的作用。针叶樱桃含有丰实的维生素C、可有效地防治坏血病。
水飞蓟:清热利湿、疏肝利胆。常用水飞蓟的提取物作为各种制剂的原料,全草用于丹毒及肿疡,果实及提取物用于治疗脾脏病,胆结石、肝脏病、慢性咳嗽、黄疸等疾病。从水飞蓟中萃取的水飞蓟素具有保肝护肝的有效成分,可以帮助肝脏清除毒素、降血脂、抗动脉粥样斑块形成,抗血小板聚集,并具有一定的修复受损肝细胞的作用,水飞蓟素的酚羟基提供氢原子,具有很强的抗氧化作用,对人体抗衰老有一定作用。
蛹虫草:降压、补肺益气、护心养脑。蛹虫草又名北冬虫夏草,北虫草等,是由子座与菌核两部分组成的复合体。蛹虫草是一种囊菌,不仅具有营养价值,而且还有一定的药用价值。是一种能同时平衡、调解阴阳的中药,具有降压、补肺益气、护心养脑等功效。1、降压:蛹虫草可以扩张血管、降血脂、有降压的作用,所以蛹虫草对改善高血压有一定疗效。2、补肺益气:蛹虫草具有很强的抗炎作用,可以清除肺内、支气管内的宿痰和垃圾,改善呼吸系统,适量食用还可以补肺益气。3、护心养脑:蛹虫草被誉为心脑血管的保护神,可以降低和预防心脑血管的发病率,清除血液中的垃圾,减少长期服药对肝、肾的损伤,营养心肌,恢复血管弹性。
谷物膳食纤维是一般不易被消化的食物营养素,主要来自于植物的细胞壁,包含纤维素、半纤维素、树脂、果胶及木质素等。膳食纤维一词在 1970年以前的营养学中尚不曾出现,在健康饮食是不可缺少的,在保持消化系统健康上扮演着重要的角色。膳食纤维主要是不能被人体利用的多糖,即不能被人类的胃肠道中消化酶所消化的,且不被人体吸收利用的多糖。在本发明中,谷物膳食纤维的来源例如可以为,但不限于大米、小麦、小米、大豆等。
白芸豆提取物是一种营养补充剂,它能阻止肠道内的消化酶,帮助消化酶吸收复杂的碳水化合物,它能使摄入的淀粉类食物通过消化系统而不经代谢。健美运动员和节食者通常使用这种补充剂来帮助减肥。
甜味剂例如可以为,但不限于葡萄糖、果糖、蔗糖、麦芽糖、淀粉糖、乳糖或木糖醇。
在一些优选的实施方式中,按重量分数计包括:
谷物膳食纤维5~15份、乳清蛋白5~15份、乳粉5~15份、针叶樱桃 5~15份、枸杞5~15份、水飞蓟5~15份、白芸豆提取物5~15份、奇亚籽 2~8份、圆苞车前子壳5~15份、蛹虫草5~15份、冬虫夏草2~8份、牡蛎肽5~15份、金线莲10~30份、卵磷脂5~15份、铁皮石斛2~8份、富硒酵母5~15份、纳豆5~15份、维生素5~15份、甜味剂2~8份、益生元5~15份和钙剂5~15份。
通过对上述配方进行进一步的筛选和优化,得到本发明提供的治疗糖尿病的药物组合物,按重量分数计包括:
谷物膳食纤维10份、乳清蛋白10份、乳粉10份、针叶樱桃10份、枸杞10份、水飞蓟10份、白芸豆提取物10份、奇亚籽5份、圆苞车前子壳10份、蛹虫草10份、冬虫夏草5份、牡蛎肽10份、金线莲20份、卵磷脂10份、铁皮石斛5份、富硒酵母10份、纳豆10份、维生素10份、甜味剂5份、益生元10份和钙剂10份。
在一些优选的实施方式中,所述维生素包括维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素D3、维生素 B12、叶酸和β-胡萝卜素中的一种或多种。
通过使用上述维生素来调整机体代谢的内环境,以调动人体的最大潜能,从而达到:1、促进肌肉的合成代谢;2、提高运动中的能量生成;3、加速训练很疲劳的消除;4、最大可能地保持检控体重的体能。
其中,维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素 B2、维生素B6、维生素D3、维生素B12、叶酸和β-胡萝卜素的用量比为 179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500。
在一些优选的实施方式中,所述甜味剂包括木糖醇。
木糖醇:1、预防龋齿;2、稳定血糖,由于木糖醇是一种可以代替白糖使用的甜味剂,可以使患者高血糖和糖尿病的人群食用,当进入人体后可以不经过胰岛素进行代谢,也能促进肝糖元合成,为人体提供能量,且糖尿病人食用以后能稳定血糖,也能减少多食,多饮以及多尿症状的发生; 3、清新口气。
在一些优选的实施方式中,所述益生元包括低聚果糖、低聚半乳糖、低聚木糖、低聚异麦芽糖、大豆低聚糖或菊粉中的一种或多种。
在一些优选的实施方式中,所述钙剂包括天门冬氨酸钙。
天门冬氨酸具有补钙的作用,属于营养强化剂,可稳定地通过胃肠部进入小肠,缓慢地释放钙离子为人体吸收,其分子结构类似于天然食物中二肽蛋白钙,最易被肠道吸收。
此外,根据本发明的第二个方面,还提供了上述治疗糖尿病的药物组合物的制备方法包括取配方中的各原料,磨粉后,得到所述治疗糖尿病的药物组合物。
该方法工艺简单,操作方便,适于产业化应用。并且,仅通过磨粉处理,能够最大程度的保留了各原料的营养及色香味,保留了原生态之完美。
在一些优选的实施方式中,磨粉后还包括过筛的步骤,优选过150~250 目筛,更有选过200目筛。
通过过筛,使得产品的性状更加稳定,且原料也更易被机体吸收利用。
下面通过具体的实施例与对比例来对本发明进行进一步的说明。
实施例1
本实施例提供了一种治疗糖尿病的药物组合物,包括:
谷物膳食纤维15份、乳清蛋白5份、乳粉15份、针叶樱桃5份、枸杞15份、水飞蓟5份、白芸豆提取物15份、奇亚籽2份、圆苞车前子壳 15份、蛹虫草5份、冬虫夏草8份、牡蛎肽5份、金线莲30份、卵磷脂5 份、铁皮石斛8份、富硒酵母5份、纳豆15份、维生素5份、甜味剂8份、益生元5份和钙剂15份。
其中,所述维生素包括质量比为 179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500的维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素 D3、维生素B12、叶酸和β-胡萝卜素。
甜味剂为乳糖。
实施例2
本实施例提供了一种治疗糖尿病的药物组合物,包括:
谷物膳食纤维5份、乳清蛋白15份、乳粉5份、针叶樱桃15份、枸杞5份、水飞蓟15份、白芸豆提取物5份、奇亚籽8份、圆苞车前子壳5 份、蛹虫草15份、冬虫夏草2份、牡蛎肽15份、金线莲10份、卵磷脂15 份、铁皮石斛2份、富硒酵母15份、纳豆5份、维生素15份、甜味剂2份、益生元15份和钙剂5份。
其中,所述维生素包括质量比为 179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500的维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素 D3、维生素B12、叶酸和β-胡萝卜素。
甜味剂为葡萄糖。
实施例3
本实施例提供了一种治疗糖尿病的药物组合物,包括:
谷物膳食纤维5份、乳清蛋白15份、乳粉5份、针叶樱桃15份、枸杞5份、水飞蓟15份、白芸豆提取物5份、奇亚籽8份、圆苞车前子壳5 份、蛹虫草15份、冬虫夏草2份、牡蛎肽15份、金线莲10份、卵磷脂15 份、铁皮石斛2份、富硒酵母15份、纳豆5份、维生素15份、甜味剂2份、益生元15份和钙剂5份。
其中,所述维生素包括质量比为 179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500的维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素 D3、维生素B12、叶酸和β-胡萝卜素。
甜味剂为木糖醇。
对比例1
本对比例提供了一种治疗糖尿病的药物组合物,与实施例1的不同之处在于不含有奇亚籽。
对比例2
本对比例提供了一种治疗糖尿病的药物组合物,与实施例1的不同之处在于不含有金线莲。
对比例3
本对比例提供了一种治疗糖尿病的药物组合物,与实施例1的不同之处在于不含有卵磷脂。
实验例
方法:高脂饲料(含糖量高)喂养4周,腹腔连续3次注射STZ,建立诱发二型糖尿病小鼠模型,感染后4周大体肉眼观察小鼠模型,明显由肥胖开始慢慢消瘦,概况毛色杂乱,精神焦躁不安,尿多。饮水量和饮食量增加,血糖值测量二组平均值11.3和11.2,证明已诱发糖尿病。
建模成功后,使用本发明实施例1-3及对比例1-3提供的治疗糖尿病的药物组合物对二型糖尿病小鼠模型进行喂养。
试验4周后,对模型组(未饲喂治疗糖尿病的药物组合物)及实验组 (饲喂本发明实施例1-3及对比例1-3提供的治疗糖尿病的药物组合物)进行体貌观察及血糖监测,结果如下表所示:
案例1
宁先生,男,70岁,糖尿病,康养前打80个单位胰岛素,早上40个单位,晚上40个单位,应用本发明实施例3提供的治疗糖尿病的药物组合物,七天停胰岛素,三个月恢复正常,有一年二个月了,能吃米饭,恢复正常生活,早上空腹血糖在6.7间。
案例2
马先生,男,58岁,8年糖尿病,打胰岛素24个单位,早晚二次二甲酸胍各两粒,早上血糖11.8,吃降压药1片,血压在142/94,停胰岛素和二甲双胍,第二天早上空腹血糖值是11.1,第二天停降压药,血压值为128/87,通过服用三个月的本发明实施例3提供的治疗糖尿病的药物组合物,血糖值在6.0左右,基本正常。
案例3
吴女士,女,49岁,8年糖尿病,康养前打胰岛素40个单位,早上20 晚上20,空腹血糖8.5,用本发明实施例3提供的治疗糖尿病的药物组合物第二天空腹血糖值为8.3,服用三个月,血糖值在6.5左右,已有二年时间完全恢复正常。
案例4
周先生,男,56岁,2年糖尿病,吃二甲双胍三次,在医院体检时血糖值为11.3,服配方当天停药,第二天血糖值为6,通过本发明实施例3提供的治疗糖尿病的药物组合物加上康养方案,三个月血糖值在6.1左右。
案例5
李先生,男,51岁,5年糖尿病,吃二甲双胍,早晚二次,测血糖为 9.4,餐后4小时,吃降压药1片,142/93,通过本发明实施例3提供的治疗糖尿病的药物组合物加康养方案,当天减药一半,早上空腹血糖值为6.0,血压123/86,三个月恢复正常。
案例6
胡女士,女,47岁,打胰岛素七年,短效28个单位,空腹血糖8.4,服本发明实施例3提供的治疗糖尿病的药物组合物加康养方案当天停胰岛素,第二天测空腹血糖6.7,通过三个月康养血糖值在5.8左右,现有二年没有反弹。
案例7
郝先生,男45岁,吃二甲双胍,血糖值11.8.用血糖仪测扎针,血是黑褐色,绸浓。使用本发明实施例3提供的治疗糖尿病的药物组合物一周血糖仪测8.1,血慢慢变红,出血快,浓度变小,这些测量数据表明血液得到净化。通过使用此配方三个月血糖恢复到6.1左右。
注:本发明案例中的“康养方案”指的是:早上吃二个鸡蛋,一碗汤。 10点左右服用本发明提供的治疗糖尿病的药物组合物,用40到50度温水冲泡。中午吃鸡肉鱼牛肉总共二两,一碗汤,尽量以绿色食品为主。下午3 点左右服用本发明提供的治疗糖尿病的药物组合物,晚上以鱼或者鸡蛋为主,一碗汤,连三天不吃米饭面条馒头和蔬菜水果。养长圣茶每天喝二包,按这种方案基本在上糖尿病三天内可以停胰岛素和西药,高血压可以停降压药,脂肪也开始下降。从第三天开始每天早餐中餐加青菜250克到500 克,在一个半月血糖血压基本稳定开始吃小米粥,总的来说此方案是采用高脂肪低碳水化物的饮食方式,康养三个月结束。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种治疗糖尿病的药物组合物,其特征在于,包括如下组分:
谷物膳食纤维、乳清蛋白、乳粉、针叶樱桃、枸杞、水飞蓟、白芸豆提取物、奇亚籽、圆苞车前子壳、蛹虫草、冬虫夏草、牡蛎肽、金线莲、卵磷脂、铁皮石斛、富硒酵母、纳豆、维生素、甜味剂、益生元和钙剂。
2.根据权利要求1所述的治疗糖尿病的药物组合物,其特征在于,按重量分数计包括:
谷物膳食纤维5~15份、乳清蛋白5~15份、乳粉5~15份、针叶樱桃5~15份、枸杞5~15份、水飞蓟5~15份、白芸豆提取物5~15份、奇亚籽2~8份、圆苞车前子壳5~15份、蛹虫草5~15份、冬虫夏草2~8份、牡蛎肽5~15份、金线莲10~30份、卵磷脂5~15份、铁皮石斛2~8份、富硒酵母5~15份、纳豆5~15份、维生素5~15份、甜味剂2~8份、益生元5~15份和钙剂5~15份。
3.根据权利要求2所述的治疗糖尿病的药物组合物,其特征在于,按重量分数计包括:
谷物膳食纤维10份、乳清蛋白10份、乳粉10份、针叶樱桃10份、枸杞10份、水飞蓟10份、白芸豆提取物10份、奇亚籽5份、圆苞车前子壳10份、蛹虫草10份、冬虫夏草5份、牡蛎肽10份、金线莲20份、卵磷脂10份、铁皮石斛5份、富硒酵母10份、纳豆10份、维生素10份、甜味剂5份、益生元10份和钙剂10份。
4.根据权利要求1所述的治疗糖尿病的药物组合物,其特征在于,所述维生素包括维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素D3、维生素B12、叶酸和β-胡萝卜素中的一种或多种。
5.根据权利要求4所述的治疗糖尿病的药物组合物,其特征在于,所述维生素C、牛磺酸、维生素E、维生素A、维生素B1、维生素B2、维生素B6、维生素D3、维生素B12、叶酸和β-胡萝卜素的质量比为179400:12000:15170:1347:1610:1670:1710:1.9:4.57:386:500。
6.根据权利要求1所述的治疗糖尿病的药物组合物,其特征在于,所述甜味剂包括木糖醇。
7.根据权利要求1所述的治疗糖尿病的药物组合物,其特征在于,所述益生元包括低聚果糖、低聚半乳糖、低聚木糖、低聚异麦芽糖、大豆低聚糖或菊粉中的一种或多种。
8.根据权利要求1所述的治疗糖尿病的药物组合物,其特征在于,所述钙剂包括天门冬氨酸钙。
9.权利要求1-8任一项所述的治疗糖尿病的药物组合物的制备方法,其特征在于,所述制备方法包括取配方中的各原料,磨粉后,得到所述治疗糖尿病的药物组合物。
10.根据权利要求9所述的制备方法,其特征在于,磨粉后还包括过筛的步骤,优选过150~250目筛,更有选过200目筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110917964.2A CN113842452A (zh) | 2021-08-11 | 2021-08-11 | 治疗糖尿病的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110917964.2A CN113842452A (zh) | 2021-08-11 | 2021-08-11 | 治疗糖尿病的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113842452A true CN113842452A (zh) | 2021-12-28 |
Family
ID=78975737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110917964.2A Pending CN113842452A (zh) | 2021-08-11 | 2021-08-11 | 治疗糖尿病的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113842452A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115998838A (zh) * | 2022-10-11 | 2023-04-25 | 广东海洋大学 | 一种具有降血糖协同增效作用的组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
CN105341906A (zh) * | 2015-10-30 | 2016-02-24 | 劲膳美生物科技股份有限公司 | 糖尿病医学配方食品 |
US20160235822A1 (en) * | 2015-02-13 | 2016-08-18 | Eastern Vision Limited | Dietary supplements and formulations |
CN111602760A (zh) * | 2019-12-25 | 2020-09-01 | 上海赋康健康管理有限公司 | 一种糖尿病非药物干预膳食营养调理食品 |
CN111685286A (zh) * | 2020-05-14 | 2020-09-22 | 中国海洋大学 | 一种具有降血脂功能的牡蛎肽及其制备方法和应用 |
CN111728214A (zh) * | 2020-08-13 | 2020-10-02 | 珠海市天顺保健食品有限公司 | 一种辅助逆转糖尿病的药食用组合物 |
-
2021
- 2021-08-11 CN CN202110917964.2A patent/CN113842452A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
US20160235822A1 (en) * | 2015-02-13 | 2016-08-18 | Eastern Vision Limited | Dietary supplements and formulations |
CN105341906A (zh) * | 2015-10-30 | 2016-02-24 | 劲膳美生物科技股份有限公司 | 糖尿病医学配方食品 |
CN111602760A (zh) * | 2019-12-25 | 2020-09-01 | 上海赋康健康管理有限公司 | 一种糖尿病非药物干预膳食营养调理食品 |
CN111685286A (zh) * | 2020-05-14 | 2020-09-22 | 中国海洋大学 | 一种具有降血脂功能的牡蛎肽及其制备方法和应用 |
CN111728214A (zh) * | 2020-08-13 | 2020-10-02 | 珠海市天顺保健食品有限公司 | 一种辅助逆转糖尿病的药食用组合物 |
Non-Patent Citations (1)
Title |
---|
陈宇勒: "养生之王 大豆营养全书", 福建科学技术出版社, pages: 150 - 193 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115998838A (zh) * | 2022-10-11 | 2023-04-25 | 广东海洋大学 | 一种具有降血糖协同增效作用的组合物及其应用 |
CN115998838B (zh) * | 2022-10-11 | 2023-08-08 | 广东海洋大学 | 一种具有降血糖协同增效作用的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101738912B1 (ko) | 비만억제 및 다이어트 조성물 | |
CN103463457B (zh) | 铁皮石斛猴头菇复配咀嚼片及其制备方法 | |
CN110771880A (zh) | 一种降糖藜麦代餐粉及其制备工艺 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN101473953A (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
CN109007856A (zh) | 一种适合高血压、高血脂、高血糖和高尿酸人群服用的代餐粉及制备方法 | |
CN112369577A (zh) | 一种阻糖美容组合物及其制备方法 | |
CN111109602A (zh) | 一种适合糖尿病及高血脂肥胖人群的药膳功能性食品 | |
CN108887564A (zh) | 一种硒蛋白杂粮粉配方及其制备方法 | |
CN106418501A (zh) | 一种具有减肥功能的保健食品 | |
CN112704237A (zh) | 一种植物肽减脂组合物及其食用方法 | |
CN105918387A (zh) | 一种适用中老年保健食品及制备方法 | |
CN102657304B (zh) | 一种具有促进消化和缓解体力疲劳双功能的保健食品 | |
CN103704568B (zh) | 临床膳食食品 | |
CN103005264B (zh) | 一种含有壳寡糖的保健食品及其制备方法 | |
CN113842452A (zh) | 治疗糖尿病的药物组合物及其制备方法 | |
CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
CN115553406A (zh) | 抑制脂肪和糖类物质吸收的减肥组合物饮料及制备方法 | |
CN114191515A (zh) | 一种祛湿健胃、提高免疫能力口服凝胶及其制备方法 | |
CN113841884A (zh) | 改善营养代谢的速溶代餐粉配方及其制作方法 | |
CN111903823A (zh) | 一种代餐食品及其制备方法 | |
CN112690386A (zh) | 一种具有抗氧化及抑菌作用并能增强心脑血管及人体免疫功能的食疗组方 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 | |
CN108685101A (zh) | 林蛙肽菊粉 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |